Clinical trials: First Line Treatment
Lymphoma, Follicular
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a…
- Trial name
- NCT02569996
- Testing
- Rituximab
- Where
- 21 sites in Hungary
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Chronic Graft Versus Host Disease
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
To study the safety and side effects of Ofatumumab in the treatment of chronic graft-versus-host disease (GvHD). This study will also evaluate effectiveness of Ofatumumab when added to standard steroid treatment for chronic…
- Trial name
- NCT01680965
- Testing
- Ofatumumab
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Cancer
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
This phase II trial studies how well temsirolimus, carboplatin, and paclitaxel as first-line therapy works in treating patients with newly diagnosed stage III-IV clear cell ovarian cancer.
- Conditions
- Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
- Trial name
- NCT01196429
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- 145 sites in United States, Japan and 1 more
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001 versus investigator's choice of chemotherapy in patients with advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02605967
- Testing
- Spartalizumab, Investigator choice of chemotherapy
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer
OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
This single arm study will evaluate the efficacy and safety of a first-line regimen of Avastin and XELOX (oxaliplatin + Xeloda) in patients with metastatic cancer of the colon or rectum.
- Trial name
- NCT00577031
- Testing
- bevacizumab [Avastin], Oxaliplatin, Xeloda
- Where
- 38 sites in Italy
- Volunteers
- 205 people
- Sponsor
- Hoffmann-La Roche
Cholangiocarcinoma
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and gemcitabine chemotherapy.
- Trial name
- PrE0204 (NCT02181634)
- Testing
- Nab-Paclitaxel and Gemcitabine
- Where
- 25 sites in United States, Austria
- Volunteers
- 74 people
- Sponsor
- PrECOG, LLC.
Follicular Lymphoma
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma.
- Trial name
- NCT02213263
- Testing
- PF-05280586, MabThera®
- Where
- 423 sites in United States, Austria and 28 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Carcinoma, Hepatocellular
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
- Trial name
- NCT03289533
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Pfizer
Renal Cell Cancer
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma.
- Trial name
- NCT00796757
- Testing
- bevacizumab [Avastin], interferon alfa-2a
- Where
- 50 sites in Czechia, Estonia and 10 more
- Volunteers
- 146 people
- Sponsor
- Hoffmann-La Roche
Metastatic Pancreatic Cancer
Anamorelin Study for Advanced Pancreatic Cancer
Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or…
- Trial name
- NCT04844970
- Testing
- Anamorelin Hydrochloride
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Lahey Clinic
Glioblastoma Multiforme
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
In this phase II trial the investigators plan to incorporate two targeted agents, bevacizumab and everolimus, into the first-line multimodality therapy of glioblastoma.
- Trial name
- NCT00805961
- Testing
- Radiation therapy, Temozolomide, Bevacizumab
- Where
- 13 sites in United States
- Volunteers
- 68 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive…
- Trial name
- FACT (NCT00256698)
- Testing
- Fulvestrant, Anastrozole
- Where
- 85 sites in Canada, Costa Rica and 10 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
This research study is being performed at approximately 3 sites associated with Accelerated Community Oncology Research Network, Inc. (ACORN). Approximately 45 subjects will take part in this study.
- Trial name
- NCT00779311
- Testing
- sorafenib, bevacizumab, mFOLFOX6 regimen
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Accelerated Community Oncology Research Network
Non-squamous, Non-Small Cell Lung Cancer
The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
This study aims to observe the sequential strategy with afatinib as first-line treatment and to find the optimal treatment strategy for long-term chemotherapy-free regimens in Chinese patients with EGFR-mutated advanced NSCLC.
- Trial name
- NCT04206787
- Testing
- Afatinib
- Where
- 10 sites in China
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
HIV, AIDS
Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa
The study design is an open-label, randomized controlled trial. The study will be conducted at study sites in Uganda and South Africa.
- Trial name
- REVAMP (NCT02787499)
- Testing
- HIV-1 RNA Resistance Testing
- Where
- 2 sites in South Africa, Uganda
- Volunteers
- 840 people
- Sponsor
- Massachusetts General Hospital
Aspergillosis, Invasive Fungal Infection
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
- Trial name
- NCT00412893
- Testing
- Isavuconazole, Voriconazole
- Where
- 107 sites in United States, Argentina and 24 more
- Volunteers
- 527 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Locally advanced or metastatic breast cancer in postmenopausal women with negative Human Epidermal Growth Factor Receptor 2 (HER2), who are candidates for hormone treatment and who have not received previous chemotherapy or…
- Trial name
- NCT00545077
- Testing
- Letrozole, Bevacizumab, Fulvestrant
- Where
- 70 sites in Germany, Spain
- Volunteers
- 380 people
- Sponsor
- Spanish Breast Cancer Research Group
Prostatic Neoplasms
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
- Trial name
- NCT00137436
- Testing
- Docetaxel, Prednisone, SU011248
- Where
- 24 sites in United States
- Volunteers
- 93 people
- Sponsor
- Pfizer
Non-Squamous Non-Small Cell Lung Cancer
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
This open-label, single arm study will assess the correlation between Tarceva (erlotinib)-induced rash and efficacy in participants with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT01174563
- Testing
- erlotinib [Tarceva]
- Where
- 16 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast…
- Trial name
- NCT00370552
- Testing
- Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg, Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg, Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 136 people
- Sponsor
- R-Pharm